Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MP0250 |
Synonyms | |
Therapy Description |
MP0250 is a protein therapeutic that targets VEGFA, HGF, and human serum albumin, resulting in decreased downstream signaling and reduced angiogenesis, and potentially leading to decreased tumor growth (PMID: 29568363, PMID: 29228696). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MP0250 | MP-0250 | MP0250 is a protein therapeutic that targets VEGFA, HGF, and human serum albumin, resulting in decreased downstream signaling and reduced angiogenesis, and potentially leading to decreased tumor growth (PMID: 29568363, PMID: 29228696). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03418532 | Phase Ib/II | MP0250 | MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | Terminated | USA | 0 |